In an in vivo model, using tumors xenograft with breast cancer cell lines in mouse, GPX4 inhibitors plus anti-PD-1-antibody significantly inhibited tumor growth compared with therapy with anti-PD-1 therapy alone. This evidence concerns the gene PDCD1 and breast carcinoma.